The GPHN Knockout Jurkat Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat E6-1 T lymphocyte line, targeting the GPHN gene. This pooled knockout model enables loss-of-function studies of gephyrin in an immortalized human immune context without clonal selection artifacts. The population-level gene disruption is generated through targeted Cas9-mediated double-strand breaks and subsequent non-homologous end joining, eliminating full-length gephyrin protein expression. Researchers receive a ready-to-use polyclonal knockout cell stock ideal for parallel biochemical, functional, and pharmacological screening experiments.
The Jurkat host cell line originates from a patient with T-cell acute lymphoblastic leukemia and serves as a foundational model for dissecting T-cell receptor signaling, mTOR pathway dynamics, and leukemia biology. Jurkat E6-1 cells express key TCR complex components and downstream effectors, providing a well-characterized cytosolic environment for exploring scaffold protein functions. This cell line permits examination of how gephyrin loss influences survival, activation, and metabolic signaling in T lymphocytes, complementing neuronal gephyrin studies with leukemia-relevant cellular physiology.
GPHN encodes gephyrin, a multidomain scaffold protein that clusters inhibitory glycine receptors (GLRB) and GABA_A receptors (subunits GABRA1, GABRB2) postsynaptically. Beyond synaptic anchoring, gephyrin catalyzes the terminal step of molybdenum cofactor (Moco) biosynthesis by interacting with MOCS1, MOCS2, and MOCS3 pathway components. Upstream regulators include mTOR and raptor, which form complexes with gephyrin and modulate its stability, while CDK5, GSK3??, PKA, and PKC phosphorylate gephyrin to control receptor clustering. Gephyrin also binds collybistin (ARHGEF9), neuroligin-2, tubulin, and profilin to coordinate cytoskeletal organization. In Jurkat cells, knockout disrupts these protein networks, potentially impairing Moco production and altering mTOR-raptor signaling, thereby connecting inhibitory synapse biology to T-cell growth and metabolism.
Loss of gephyrin in Jurkat cells provides a unique model for studying Moco deficiency and hyperekplexia etiology in an immune-relevant system, while revealing mTOR pathway perturbations that may impact leukemogenesis. Since gephyrin participates in mTOR-raptor complexes, knockout cells enable dissection of mTOR-dependent proliferation and survival signals distinct from conventional mTOR inhibitor studies. This model also facilitates investigation of cross-talk between molybdenum cofactor availability and amino acid sensing pathways in T cells, offering insights into metabolic vulnerabilities in leukemia.
Typical applications include functional characterization of gephyrin in T lymphocytes using western blotting, immunoprecipitation, and RT-qPCR to quantify downstream targets such as GLRB and MOCS enzymes. Moco biosynthesis assays and cell viability assays permit direct measurement of enzymatic activity and proliferative capacity. Flow cytometry and drug sensitivity testing enable screening for compounds that restore Moco-dependent functions or modulate mTOR hyperactivation. The polyclonal knockout format supports pooled functional genomics screens and arrayed compound testing without confounding clonal effects. For further technical details or custom experimental design, please contact Ascent Research.
